证券代码：603392 证券简称：万泰生物 公告编号：2025-055 北京万泰生物药业股份有限公司 关于注销部分回购股份并减少注册资本 暨通知债权人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次回购股份注销完成后，公司股份总数将由1,265,122,774股减少至 1,264,392,804股，注册资本将由1,265,122,774元减少为1,264,392,804元。 二、需债权人知晓的相关信息 一、通知债权人的原由 北京万泰生物药业股份有限公司（以下简称"公司"）于2025年10月15日召 开第六届董事会第十次会议、第六届监事会第十次会议，审议通过了《关于变更 部分回购股份用途并注销的议案》。公司拟将回购专用证券账户中已回购但尚未 使用的729,970股股份用途由"用于员工持股计划或股权激励"变更为"用于注 销并减少注册资本"。以上议案已经2025年10月31日召开的公司2025年第一次临 时股东会审议通过。具体内容详见公司于2025年10月16日、2025年11月1日在指 定信息披露媒体披露的《北京万泰生 ...

Group 1 - The core point of the article is the inclusion of the HPV vaccine in the national immunization program starting from November 10, 2025, providing free vaccinations for girls born after November 10, 2011, who are 13 years old or older [1] - The initiative aims to maximize prevention effectiveness and reduce the incidence and mortality rates of cervical cancer, based on WHO recommendations and China's national conditions [1] - The Chinese Center for Disease Control and Prevention (CDC) will be responsible for aggregating vaccine demand and conducting centralized procurement, with a budget of 425 million yuan [1] Group 2 - The HPV vaccine to be provided is the bivalent type, with a recommended two-dose schedule spaced six months apart [1] - The suppliers for the vaccine will be Wantai Biological Pharmacy and Watson Biotech, which is expected to enhance vaccination rates and promote health equity [1]

Group 1 - The inclusion of the HPV vaccine in the national immunization program marks a significant breakthrough in public health in China, with over 10 million eligible girls expected to benefit annually from the free vaccination policy starting November 10, 2025 [1][2] - The two-valent HPV vaccine can prevent approximately 70% of cervical cancer cases, which is a major advancement in cervical cancer prevention [1][5] - The market demand for HPV vaccines is projected to reach tens of millions of doses annually, with the market size expected to exceed 10 billion RMB, indicating a substantial growth opportunity for domestic vaccine manufacturers [1][5][6] Group 2 - The government has allocated a budget of approximately 425 million RMB for the centralized procurement of the two-valent HPV vaccine, with an estimated procurement price of 27.5 RMB per dose [5] - The total market size for the national immunization program from 2025 to 2030 is estimated to be around 3.8 billion RMB, which includes both new eligible girls and existing populations needing booster shots [5][6] - The policy is expected to enhance public awareness and willingness to receive HPV vaccinations, potentially increasing demand for self-paid vaccinations among other age groups [5][6] Group 3 - Domestic vaccine companies such as Wantai Biological Pharmacy and Watson Bio are leading the charge in the HPV vaccine market, with significant advancements in technology and production capacity [6][8] - Wantai Biological's two-valent HPV vaccine was the first domestically produced vaccine to break the monopoly of imported vaccines, and the company has also developed the first nine-valent HPV vaccine in China [8][9] - The competition among domestic companies is expected to ensure supply security and drive technological innovation, while also reducing costs and enhancing industry safety and self-sufficiency [9]

Core Insights - The company reported a significant decline in revenue and net profit for the first three quarters of 2025, with total revenue at 1.5 billion yuan, down 23.1% year-on-year, and a net loss of 173 million yuan, down 165.0% year-on-year [1] - In Q3 2025, the company experienced a revenue increase of 12.5% year-on-year, totaling 655 million yuan, but still reported a net loss of 29.38 million yuan, a decline of 576.3% year-on-year [1] - The company’s non-recurring net profit also worsened, with a loss of 650.1 million yuan compared to a loss of 225.2 million yuan in the same period last year, marking an 850.4% decline [1] Business Developments - During the reporting period, the company completed the batch release of 9 batches of its nine-valent HPV vaccine, gained access in 16 provinces, and initiated first vaccinations in 7 provinces/regions [1] - The international business of the vaccine showed robust growth, with approximately 15.05 million doses exported, representing a threefold increase compared to 2024 and a sixfold increase compared to 2023 [1] - As of the end of the reporting period, the company’s vaccine received market access in 24 overseas countries, including Angola, Pakistan, and Belarus [1]

Group 1 - Wantaibio (603392.SH) reported its Q3 2025 results, with 12 institutional investors holding a total of 731 million shares, representing 57.77% of the total share capital [1] - The top ten institutional investors include major entities such as YS Health, Hong Kong Central Clearing, and various index funds, collectively holding 57.76% of shares, a decrease of 2.67 percentage points from the previous quarter [1] Group 2 - In the public fund sector, four funds increased their holdings, including Huaxia National Bio-Medical Index Fund and others, with a slight increase in holding percentage [2] - Five public funds reduced their holdings, with a total decrease of 0.10%, including funds like China National Bio-Medical Index A and others [2] - One new public fund was disclosed this period, while 253 funds were not disclosed compared to the previous quarter, indicating significant turnover in fund disclosures [2]

Core Insights - The company reported a significant decline in revenue and net profit for the first three quarters of 2025, with total revenue at 1.5 billion yuan, down 23.1% year-on-year, and a net loss of 173 million yuan, a decrease of 165.0% compared to the previous year [1][1][1] Financial Performance - In Q3 2025, the company achieved revenue of 655 million yuan, reflecting a year-on-year increase of 12.5% [1] - The net profit attributable to shareholders for Q3 was a loss of 29.38 million yuan, marking a decline of 576.3% year-on-year [1] - The adjusted net profit loss for Q3 widened to 65.01 million yuan from a loss of 22.52 million yuan in the same period last year [1] Asset and Equity Position - As of the end of Q3, the company's total assets stood at 14.371 billion yuan, a decrease of 2.2% from the end of the previous year [1] - The net assets attributable to shareholders were 12.089 billion yuan, down 1.4% from the end of the previous year [1] Business Development - The company highlighted its business developments in the Q3 report, focusing on vaccine research and production, as well as in vitro diagnostic (IVD) product development and related services [1] - During the reporting period, the company launched a nine-valent HPV vaccine and received approval for nine nucleic acid testing kits for respiratory pathogens, enhancing its molecular diagnostic product line [1] - The company also introduced a comprehensive nucleic acid testing solution for respiratory diseases, catering to various medical scenarios and improving testing efficiency [1]

证券代码：603392 证券简称：万泰生物 公告编号：2025-052 北京万泰生物药业股份有限公司 关于全资子公司出售资产暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 交易内容：北京万泰生物药业股份有限公司（以下简称"公司"）拟将全 资子公司杭州万泰生物技术有限公司（以下简称"杭州万泰"）名下持有的无法 再利用的装修类长期待摊费用及固定资产出售给养生堂有限公司(以下简称"养 生堂")。杭州万泰拟与养生堂签署《资产转让协议》，本次交易价格为 18,958.52 万元（不含增值税，下同），系根据评估机构出具的《资产评估报告》确定。 养生堂为公司控股股东，杭州万泰为公司全资子公司，本次交易构成关 联交易，但不构成《上市公司重大资产重组管理办法》规定的重大资产重组。 本次交易已经公司第六届董事会独立董事第一次专门会议、第六届董事 会审计委员会第九次会议、第六届董事会第十一次会议和第六届监事会第十一次 会议审议通过，无需提交公司股东会审议。 截至本次关联交易，过去 12 个月内公司与同一关联人进行的 ...

证券代码：603392 证券简称：万泰生物 公告编号：2025-053 北京万泰生物药业股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 11 月 11 日（星期二）上午 11:00-12:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 4 日（星期二）至 11 月 10 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 wtzqb@ystwt.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 北京万泰生物药业股份有限公司（以下简称"公司"）已于 2025 年 10 月 30 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财 ...

证券代码：603392 证券简称：万泰生物 公告编号：2025-051 北京万泰生物药业股份有限公司 第六届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 北京万泰生物药业股份有限公司（以下简称"公司"）于2025年10月26日以 电子邮件方式向全体监事发出第六届监事会第十一次会议召开通知和会议材料。 本次会议于2025年10月29日以通讯方式召开。本次会议由公司监事会主席邢庆超 先生主持，应出席监事3人，实际出席监事3人。本次会议的出席人数、召开和表 决方式符合《公司法》等法律、法规及《公司章程》的相关规定，合法有效。 二、监事会会议审议情况 1、审议通过了《关于公司2025年第三季度报告的议案》 监事会认为： 限公司(以下简称"养生堂")。杭州万泰拟与养生堂签署《资产转让协议》，本 次交易价格为18,958.52万元（不含增值税），系根据评估机构浙江中联资产评估 有限公司出具的《资产评估报告》确定。 具体内容详见公司于指定信息披露媒体披露的《北京万泰生物药业股份有限 公司 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603392 证券简称：万泰生物 公告编号：2025-050 北京万泰生物药业股份有限公司 第六届董事会第十一次会议决议公告 该议案已经第六届董事会审计委员会审议通过。 2、审议通过了《关于全资子公司出售资产暨关联交易的议案》 同意公司全资子公司杭州万泰生物技术有限公司（以下简称"杭州万泰"） 将其名下持有的无法再利用的装修类长期待摊费用及固定资产出售给养生堂有 限公司(以下简称"养生堂")。杭州万泰拟与养生堂签署《资产转让协议》，本 次交易价格为 18,958.52 万元（不含增值税），系根据评估机构浙江中联资产评 估有限公司出具的《资产评估报告》确定。 具体内容详见公司于指定信息披露媒体披露的《北京万泰生物药业股份有限 公司关于全资子公司出售资产暨关联交易的公告》（公告编号：2025-052）。 表决结果：同意 5 票、反对 0 票、弃权 0 票。 一、董事会会议召开情况 北京万泰生物药业股份有限公司（以下简称"公司"）于2025年10月26日以 电子邮件方式向全体 ...